TY - JOUR
T1 - Patient-derived xenograft (PDX) models in basic and translational breast cancer research
AU - Dobrolecki, Lacey E.
AU - Airhart, Susie D.
AU - Alferez, Denis G.
AU - Aparicio, Samuel
AU - Behbod, Fariba
AU - Bentires-Alj, Mohamed
AU - Brisken, Cathrin
AU - Bult, Carol J.
AU - Cai, Shirong
AU - Clarke, Robert B.
AU - Dowst, Heidi
AU - Ellis, Matthew J.
AU - Gonzalez-Suarez, Eva
AU - Iggo, Richard D.
AU - Kabos, Peter
AU - Li, Shunqiang
AU - Lindeman, Geoffrey J.
AU - Marangoni, Elisabetta
AU - McCoy, Aaron
AU - Meric-Bernstam, Funda
AU - Piwnica-Worms, Helen
AU - Poupon, Marie France
AU - Reis-Filho, Jorge
AU - Sartorius, Carol A.
AU - Scabia, Valentina
AU - Sflomos, George
AU - Tu, Yizheng
AU - Vaillant, François
AU - Visvader, Jane E.
AU - Welm, Alana
AU - Wicha, Max S.
AU - Lewis, Michael T.
N1 - Funding Information:
Peter Kabos—NIH grant CA164048, Grohne Cancer Research Fund
Funding Information:
Michael T. Lewis—This work was supported in part by the Breast Cancer Research Foundation, the Emma Jacobs Clinical Breast Cancer Fund, the Susan G. Komen Foundation, Cancer Fighters of Houston, BCM Cancer Center grant P30 CA125123, BCM Breast Cancer SPORE P50 CA50183, NIH/NCI grant R01 CA112305, and NIH/NCI grant U54 CA149196. The authors also acknowledge the joint participation by Diana Henry Helis Medical Research Foundation through its direct engagement in the continuous active conduct of medical research in conjunction with Baylor College of Medicine and its “Blood-borne BioMarkers for Detection of Breast Cancer” Program.
Funding Information:
Richard Iggo—This work was supported by the “Fondation pour la lutte contre le cancer et pour des recherches medico-biologiques,” the INCa-DGOS-INSERM 6046 SIRIC BRIO grant, and the French Cancer League (Comité de la Charente Maritime).
Funding Information:
Cathrin Brisken—The research leading to these results has received support from the Swiss Cancer League, the SNF, and the Innovative Medicines Initiative Joint Undertaking (grant agreement no. 115188) for the PREDECT consortium ( www.predect.eu ) resources composed of financial contribution from EU-FP7 and EFPIA companies in kind contribution. The Web address of the Innovative Medicines Initiative is http://www.imi.europa.eu/ .
Funding Information:
Robert Clarke and Denis Alferez—This work was funded by Cancer Research UK and Breast Cancer Now. We would like to thank all patients who donated tissue to this study and the Manchester Cancer Research Centre Biobank for consenting patients and collecting tissue.
Funding Information:
Alana Welm—The Noreen Fraser Foundation, METAvivor Foundation, AACR Susan G. Komen Career Catalyst award, DOD Breast Cancer Research Program grants W81XWH-08-1-0109 and BC112623, and NIH/NCI grants 1R01CA166422 and 1R01CA173903
Funding Information:
Shunqiang Li—Susan G. Komen for the Cure (BCTR0707808, KG090422, and PG12220321), Breast Cancer Research Foundation, CTSA grant UL1 RR024992, and The Fashion Footwear Charitable Foundation, Inc.
Funding Information:
Carol J. Bult—This work was supported in part by the Maine Cancer Foundation, The Jackson Laboratory Director’s Innovation Fund, and JAX Cancer Center grant P30 CA034196.
Funding Information:
Helen Piwnica-Worms—This work was supported in part by the Cazalot Breast Cancer Model Resource, The Susan G. Komen Foundation, and The Cancer Prevention and Research Institute of Texas (CPRIT) RP150148.
Funding Information:
Geoffrey J. Lindeman and Jane E. Visvader—Received funding support from the Australian National Health and Medical Research Council (NHMRC; 1016701, 1040978, 1086727, 1085191); NHMRC Independent Research Institute Infrastructure Support Scheme (IRIISS) (to WEHI); the Victorian State Government through the Victorian Cancer Agency and Operational Infrastructure Support; the National Breast Cancer Foundation (Australia); the Cancer Therapeutics CRC; and the Australian Cancer Research Foundation. G.J.L. is supported by an NHMRC Research Fellowship (1078730); J.E.V. is supported by an NHMRC Australia Fellowship (1037230).
Funding Information:
Max Wicha—R35: CA129765; RO1 CA101860, Komen for the Cure Promise grant, and Breast Cancer Research Foundation grant
Funding Information:
Eva Gonzalez-Suarez—This work was supported in part by grants to Eva González Suárez by the Spanish Ministry of Economy and Competitivity MINECO and from the ISCIII (SAF2008-01975, SAF2011-22893, SAF2014-55997), PIE13/00022, co-funded by FEDER funds/European Regional Development Fund (ERDF—a way to build Europe), by a Career Catalyst grant from the Susan Komen Foundation and by institutional funds provided by the Generalitat de Catalunya.
Funding Information:
Jorge Reis-Filho—Research reported in this publication was supported in part by a grant from the Breast Cancer Research Foundation and a Cancer Center Support grant of the National Institutes of Health/National Cancer Institute (grant no. P30CA008748). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Publisher Copyright:
© 2016, Springer Science+Business Media New York.
PY - 2016/12/1
Y1 - 2016/12/1
N2 - Patient-derived xenograft (PDX) models of a growing spectrum of cancers are rapidly supplanting long-established traditional cell lines as preferred models for conducting basic and translational preclinical research. In breast cancer, to complement the now curated collection of approximately 45 long-established human breast cancer cell lines, a newly formed consortium of academic laboratories, currently from Europe, Australia, and North America, herein summarizes data on over 500 stably transplantable PDX models representing all three clinical subtypes of breast cancer (ER+, HER2+, and “Triple-negative” (TNBC)). Many of these models are well-characterized with respect to genomic, transcriptomic, and proteomic features, metastatic behavior, and treatment response to a variety of standard-of-care and experimental therapeutics. These stably transplantable PDX lines are generally available for dissemination to laboratories conducting translational research, and contact information for each collection is provided. This review summarizes current experiences related to PDX generation across participating groups, efforts to develop data standards for annotation and dissemination of patient clinical information that does not compromise patient privacy, efforts to develop complementary data standards for annotation of PDX characteristics and biology, and progress toward “credentialing” of PDX models as surrogates to represent individual patients for use in preclinical and co-clinical translational research. In addition, this review highlights important unresolved questions, as well as current limitations, that have hampered more efficient generation of PDX lines and more rapid adoption of PDX use in translational breast cancer research.
AB - Patient-derived xenograft (PDX) models of a growing spectrum of cancers are rapidly supplanting long-established traditional cell lines as preferred models for conducting basic and translational preclinical research. In breast cancer, to complement the now curated collection of approximately 45 long-established human breast cancer cell lines, a newly formed consortium of academic laboratories, currently from Europe, Australia, and North America, herein summarizes data on over 500 stably transplantable PDX models representing all three clinical subtypes of breast cancer (ER+, HER2+, and “Triple-negative” (TNBC)). Many of these models are well-characterized with respect to genomic, transcriptomic, and proteomic features, metastatic behavior, and treatment response to a variety of standard-of-care and experimental therapeutics. These stably transplantable PDX lines are generally available for dissemination to laboratories conducting translational research, and contact information for each collection is provided. This review summarizes current experiences related to PDX generation across participating groups, efforts to develop data standards for annotation and dissemination of patient clinical information that does not compromise patient privacy, efforts to develop complementary data standards for annotation of PDX characteristics and biology, and progress toward “credentialing” of PDX models as surrogates to represent individual patients for use in preclinical and co-clinical translational research. In addition, this review highlights important unresolved questions, as well as current limitations, that have hampered more efficient generation of PDX lines and more rapid adoption of PDX use in translational breast cancer research.
KW - Breast cancer
KW - Immunocompromised/immunodeficient mice
KW - PDX consortium
KW - Patient-derived xenograft
KW - Translational research
UR - http://www.scopus.com/inward/record.url?scp=85007193603&partnerID=8YFLogxK
U2 - 10.1007/s10555-016-9653-x
DO - 10.1007/s10555-016-9653-x
M3 - Article
C2 - 28025748
AN - SCOPUS:85007193603
VL - 35
SP - 547
EP - 573
JO - Cancer and Metastasis Reviews
JF - Cancer and Metastasis Reviews
SN - 0167-7659
IS - 4
ER -